-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| AIDS vaccine trial meets another setback |
This study once again shows that it is difficult to stop HIV with vaccines
.
Image source: JAMES CAVALLINI
People's decades-long attempts to find an effective AIDS vaccine have again met with frustrating results, and another large-scale trial of a vaccine has failed
.
In a trial called Imbokodo that began in 2017, a vaccine produced by Johnson & Johnson failed to provide convincing protection against HIV infection
.
The trial involved 2,600 women in South Africa and its four neighboring countries
This trial compared the efficacy of the vaccine with a placebo
.
The results announced by Johnson & Johnson in a statement on August 31 showed that 63 people in the placebo group were infected, while 51 of the participants who received the vaccine were infected, and the effectiveness of the vaccine was 25.
However, Gray emphasized that the data provided by the Imbokodo project is more promising than the other two AIDS vaccine efficacy trials she participated in
.
"Every failed trial tells us something
Johnson & Johnson Chief Scientific Officer Paul Stoffels said that despite the failure, a second trial of similar vaccines in different study populations will continue
.
The Mosaico trial, which began in the Americas and Europe in 2019, involved 3,800 transgender people and men who had sex with them
Both Imbokodo and Mosaico have a total of four doses, using two different injections
.
The first shot uses the same backbone as Johnson & Johnson's new coronavirus product: adenovirus 26, which is a harmless "vector" that transmits 4 HIV genes to human cells
NIAID's AIDS Vaccine Trial Network sponsored these two studies
.
Lawrence Corey, a vaccine researcher at the Fred Hutchinson Cancer Research Center and co-leader of the network, pointed out that Johnson & Johnson’s strategy relies heavily on triggering the production of T cells that can recognize and eliminate HIV-infected cells.
Corey said that several research groups have begun human trials of vaccines designed to stimulate effective neutralization of HIV antibodies, but perhaps none of them will be able to enter a full effectiveness trial in about four years
.
"We have a lot of work to do
Related article information:
doi: 10.
